Suresh Nair

7PUBLICATIONS
90CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer, Axel Bex, Paul Russo

|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy, Hannah L Kalvin, Fiona D Ehrich

|Jul 27, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson

|Jan 05, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.

Jonathan A Coleman, Wesley Yip, Nathan C Wong

|Aug 11, 2022
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

Frank A Sinicrope, Qian Shi, Aurelie Catteau

|Dec 20, 2021
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

Michael A Postow, Debra A Goldman, Alexander N Shoushtari

Pageof 2

Frequent Collaborators

2 joint publications

Michael A Postow

2 joint publications

Debra A Goldman

2 joint publications

Alexander N Shoushtari

2 joint publications

Allison Betof Warner